• 1. 第四軍醫(yī)大學(xué)研究生大隊(duì)(西安710032)2. 第四軍醫(yī)大學(xué)病理學(xué)教研室3. 第四軍醫(yī)大學(xué)西京醫(yī)院;

為探討抗凋亡基因bcl-2與膽囊腫瘤發(fā)生、分化及臨床預(yù)后的關(guān)系，采用免疫組織化學(xué)方法對45例原發(fā)性膽囊癌和39例膽囊腺瘤抗凋亡基因bcl-2的表達(dá)進(jìn)行了觀察。結(jié)果顯示：bcl-2在原發(fā)性膽囊癌和膽囊腺瘤的表達(dá)率分別為71.1%和87.2%，兩者比較無顯著性差異(Ｐ＞0.05)；bcl-2在原發(fā)性膽囊癌高、中、低分化型的表達(dá)率分別為82.3%、82.4%和50.0%，彼此間存在顯著性差異(Ｐ＜0.01)；bcl-2表達(dá)在原發(fā)性膽囊癌臨床Ⅰ～Ⅱ期與Ⅲ期的陽性率分別為81.3%、65.3%，彼此間無顯著性差異，表明bcl-2表達(dá)可能與原發(fā)性膽囊癌臨床分期無直接關(guān)系。

引用本文： 徐宏勇,王文勇,閻慶國,李開宗. 抗凋亡基因bcl-2在原發(fā)性膽囊癌中的表達(dá)及其臨床意義. 中國普外基礎(chǔ)與臨床雜志, 1998, 5(2): 73-74. doi: 復(fù)制

版權(quán)信息： ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有，未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14∶18) chromosome translocation. Science, 1984; 226(4678)∶1097.
2. Frank AS, San Bao R, Karen RC, et al. bcl2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Research, 1995; 55(2)∶237.
3. 徐宏勇，閻慶國，方馳華等. 凋亡相關(guān)基因bcl2和bax在結(jié)腸腫瘤的表達(dá)及意義. 天津醫(yī)藥， 1997； 25(8)∶459.
4. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin fixed paraffin embeded tissues: an enbancement method for immunohistochemical staining based upon microwave oven heating of tissue sections. J Histochem Cytochem, 1991; 39(6)∶741.
5. Hino N, Higashi T, Nouso K, et al. Apoptosis and proliferation of human hepatocellular carcinoma. Liver, 1996; 16(3)∶123.
6. Hellemans P, Van Dam PA, Weiler J, et al. Prognostic value of bcl2 expression in invasive breast cancer. Br J Cancer, 1995; 72(2)∶354.
7. Henriksen R, Willander E, Berg K. Expression and prognostic significance of bcl2 in ovarian tumors. Br J Cancer, 1995; 72(10)∶1324.
8. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl2 immunoreactivity in medullary thyroid carcinoma. Human patho, 1995; 26(9)∶945.
9. Lauwers GY, Scott GV, Karpeh MS. Immunohistechemical evaluation of bcl2 protein expression in gastric adenocarcinomas. Cancer, 1995; 75(9)∶2209.
  1. 1. Tsujimoto Y, Finger LR, Yunis J, et al. Cloning of the chromosome breakpoint of neoplastic B cells with the t(14∶18) chromosome translocation. Science, 1984; 226(4678)∶1097.
  2. 2. Frank AS, San Bao R, Karen RC, et al. bcl2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Research, 1995; 55(2)∶237.
  3. 3. 徐宏勇，閻慶國，方馳華等. 凋亡相關(guān)基因bcl2和bax在結(jié)腸腫瘤的表達(dá)及意義. 天津醫(yī)藥， 1997； 25(8)∶459.
  4. 4. Shi SR, Key ME, Kalra KL. Antigen retrieval in formalin fixed paraffin embeded tissues: an enbancement method for immunohistochemical staining based upon microwave oven heating of tissue sections. J Histochem Cytochem, 1991; 39(6)∶741.
  5. 5. Hino N, Higashi T, Nouso K, et al. Apoptosis and proliferation of human hepatocellular carcinoma. Liver, 1996; 16(3)∶123.
  6. 6. Hellemans P, Van Dam PA, Weiler J, et al. Prognostic value of bcl2 expression in invasive breast cancer. Br J Cancer, 1995; 72(2)∶354.
  7. 7. Henriksen R, Willander E, Berg K. Expression and prognostic significance of bcl2 in ovarian tumors. Br J Cancer, 1995; 72(10)∶1324.
  8. 8. Viale G, Roncalli M, Grimelius L, et al. Prognostic value of bcl2 immunoreactivity in medullary thyroid carcinoma. Human patho, 1995; 26(9)∶945.
  9. 9. Lauwers GY, Scott GV, Karpeh MS. Immunohistechemical evaluation of bcl2 protein expression in gastric adenocarcinomas. Cancer, 1995; 75(9)∶2209.